Melfalan Sun

Melphalan, the active ingredient in Melfalan Sun, is an alkylating agent presented as an intravenous formulation for use in oncology patients. It is employed in the treatment of certain blood cancers and solid tumours, targeting rapidly dividing malignant cells.

GNH USA supplies Melfalan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with manufacturing adhering to EU GMP standards and export documentation for global distribution. The product is shipped under controlled conditions to maintain stability.

Melphalan is an alkylating chemotherapy agent used in the treatment of certain hematologic malignancies and solid tumours. - Multiple myeloma: helps reduce malignant plasma cells and prolong remission. - Ovarian cancer: used as part of combination regimens to target tumor growth. - Malignant melanoma: employed in selected cases to achieve cytoreduction.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset frequently reported during treatment. - Alopecia: reversible hair loss affecting scalp and body hair. - Fatigue: persistent tiredness that may limit daily activities. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Diarrhea: loose stools that can lead to dehydration. - Myelosuppression: reduced blood cell counts causing anemia or infection risk.

Serious or Rare Side Effects: - Aplastic anemia: severe bone‑marrow failure requiring transfusion support. - Secondary leukemia: development of a new leukemic disorder after prolonged exposure. - Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnea. - Renal toxicity: impaired kidney function, especially with high cumulative doses. - Severe neutropenia: markedly low neutrophil count increasing infection susceptibility.

Precautions should be observed before and during melphalan therapy. - Dose adjustment: required for patients with renal or hepatic impairment. - Monitoring: regular complete blood counts to detect myelosuppression. - Pregnancy: avoid use unless benefits outweigh potential fetal risks. - Concomitant therapy: do not administer live vaccines during treatment. - Administration: ensure aseptic technique for intravenous infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan may interact with several medications; awareness of interaction severity is essential. Major Interactions (Avoid): - Live vaccines: may cause severe infection in immunocompromised patients. - Concurrent use with other alkylating agents: increased risk of cumulative toxicity. - High-dose radiation therapy: enhanced tissue damage when combined. Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may alter melphalan clearance. - CYP450 inhibitors: potential increase in melphalan plasma levels. - Nephrotoxic drugs (e.g., aminoglycosides): heightened risk of renal impairment.